BONCRESA
LaunchmAbdenosumab-mobz
BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BONCRESA (denosumab-mobz) is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONCRESA (denosumab-mobz) is a monoclonal antibody that blocks RANK ligand, a key mediator of bone resorption. This biosimilar candidate targets conditions characterized by pathological bone loss, though specific indications are not disclosed in available data. It represents a subcutaneous injectable biologic approach to managing bone metabolism disorders.
Launch
As a newly launched biosimilar entering a moderate-competitive market (30% pressure), commercial teams will focus on rapid market penetration and payer access strategies.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BONCRESA represents a biosimilar launch opportunity in a competitive market, creating roles in payer negotiation, provider education, and field execution. Career progression will be driven by successful market share capture and operational efficiency in a cost-focused segment.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.